Journal
VACCINE
Volume 37, Issue 1, Pages 137-144Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2018.11.021
Keywords
Human papillomavirus; Minor capsid protein; Recombinant immune complex; Virus-like particle; Vaccine
Categories
Funding
- NIH-NIAID [U19-AI062150-01]
- Center for Immunotherapy, Vaccines, and Virotherapy of the Biodesign Insitute at ASU
Ask authors/readers for more resources
Diverse HPV subtypes are responsible for considerable disease burden worldwide, necessitating safe, cheap, and effective vaccines. The HPV minor capsid protein L2 is a promising candidate to create broadly protective HPV vaccines, though it is poorly immunogenic by itself. To create highly immunogenic and safe vaccine candidates targeting L2, we employed a plant-based recombinant protein expression system to produce two different vaccine candidates: L2 displayed on the surface of hepatitis B core (HBc) virus-like particles (VLPs) or L2 genetically fused to an immunoglobulin capable of forming recombinant immune complexes (RIC). Both vaccine candidates were potently immunogenic in mice, but were especially so when delivered together, generating very consistent and high antibody titers directed against HPV L2 (>1,000,000) that correlated with virus neutralization. These data indicate a novel immune response synergy upon co-delivery of VLP and RIC platforms, a strategy that can be adapted generally for many different antigens. (C) 2018 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available